Design and Study Sample

This retrospective database study assessed the effects of flash CGM system acquisition on occurrence rates of ADE and ACH within a large cohort of patients with type 2 diabetes treated with short- or rapid-acting insulin therapy. Both analysis structure and outcomes were prespecified. Patients were included if they had a diagnosis of type 2 diabetes, were ≥ 18 years of age, received a prescription for short- or rapid-acting insulin, were naïve to CGM, and acquired either the 10-day or 14-day sensor system between November 2017 and September 2018. In addition, patients were required to be continuously enrolled in the inpatient, outpatient, and pharmacy databases for at least 6 months prior to system acquisition.

Diabetes type was determined from the closest relevant diagnosis claim prior to flash CGM acquisition. In the rare case the closest claim had billing codes related to both type 1 and type 2 diabetes, the patient was not included. In addition, patients with a gestational diabetes diagnosis in the 6 months prior to flash CGM acquisition were excluded.